Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puma Biotechnology (NQ: PBYI )

3.390 +0.160 (+4.95%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology

< Previous 1 2 3 4 5 6 7 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2021
Upgrades For Bouygues (OTC:BOUYF), Jefferies upgr... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data, Fed Speakers
Pre-open movers U.S. stock futures traded lower in early pre-market trade after closing mixed in the previous session. Investors are awaiting earnings results from FactSet... 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
How Bad Are Puma Biotechnology's Earnings? | Return on Capital Employed
Puma Biotechnology (NASDAQ:PBYI) brought in sales totaling $53.40 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 183.33%, resulting in a... 
Via Benzinga
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Second Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low... 
Via Benzinga
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports First Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.